Sumary of Bovine-derived polyclonal antibodies exhibit high efficacy in neutralizing SARS-CoV-2 variants:
- A team of scientists in Estonia has recently evaluated the therapeutic/prophylactic efficacy of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) polyclonal antibodies derived from the colostrum of immunized cows..
- The antibodies exhibit high efficiency in inhibiting the interaction between SARS-CoV-2 spike protein and human angiotensin-converting enzyme 2 (ACE2)..
- Furthermore, the scientists have prepared a nasal spray formulation with colostrum antibodies that persists in the human nasal mucosa for at least 4 hours..
- Background As of June 10, 2021, globally, there have been 173 million confirmed cases of coronavirus disease 2019 (COVID-19), including 3.7 million deaths, registered to the World Health Organization (WHO)..
- This could potentially be due to the emergence of novel viral variants with multiple spike mutations, which are able to escape host immunity developed in response to natural infection or vaccination..
- In both clinical trials and real-world situations, neutralizing monoclonal antibodies have shown good therapeutic and prophylactic efficiencies against SARS-CoV-2 infection..
- In the majority of the cases, neutralizing antibodies are developed against the viral spike protein, which prevents SARS-CoV-2 host cell entry by binding to the spike protein, and thus, inhibiting the spike – ACE2 attachment..
- Thus, passive immunization with neutralizing antibodies is particularly helpful in preventing SARS-CoV-2 infection at the early stage….